Literature DB >> 9256153

Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter.

G DiDiodato1, F J Sharom.   

Abstract

P-Glycoprotein functions as an ATP-driven efflux pump for hydrophobic natural products and peptides, and gives rise to resistance to multiple chemotherapeutic drugs. The inhibition of colchicine transport via P-glycoprotein by various compounds was determined in a plasma membrane vesicle model system. A chemotherapeutic drug (vinblastine) and several chemosensitizers (verapamil, reserpine, cyclosporin A) and hydrophobic peptides (N-acetyl-leucyl-leucyl-methioninal, leupeptin, pepstatin A, valinomycin) were examined, both as individual species and as combinations of compounds. The median effect analysis was used to determine the concentration of each combination required to produce a median effect, Dm, as well as the sigmoidicity of the concentration-effect plot, m. The combination of cyclosporin A and verapamil was the only one established to be mutually nonexclusive, whereas several mutually exclusive pairs of compounds were identified. The combination index, CI, was calculated for several combinations of drugs, chemosensitizers, and peptides, and used to ascertain whether effects were synergistic, antagonistic, or additive. Some combinations (vinblastine/verapamil; verapamil/valinomycin) showed antagonism over the entire concentration range. Other combinations (valinomycin/N-acetyl-leucyl-leucyl-methioninal; cyclosporin A/verapamil) displayed both synergism and antagonism over different regions of the CI plot. Many combinations of compounds displayed additive interactions over most of the CI plot. The median effect analysis may be helpful in identifying potentially useful additive or synergistic combinations of compounds for reversal of Pgp-mediated drug resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256153     DOI: 10.1016/s0006-2952(97)00007-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux.

Authors:  José M Pérez-Victoria; Fernando Cortés-Selva; Adriana Parodi-Talice; Boris I Bavchvarov; F Javier Pérez-Victoria; Francisco Muñoz-Martínez; Mathias Maitrejean; M Paola Costi; Denis Barron; Attilio Di Pietro; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation.

Authors:  F J Sharom; P Lu; R Liu; X Yu
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

3.  In situ localization of P-glycoprotein (ABCB1) in human and rat brain.

Authors:  Reina Bendayan; Patrick T Ronaldson; Diane Gingras; Moise Bendayan
Journal:  J Histochem Cytochem       Date:  2006-06-26       Impact factor: 2.479

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 5.  Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).

Authors:  Sascha C T Nicklisch; Amro Hamdoun
Journal:  FEBS Lett       Date:  2020-12-09       Impact factor: 4.124

6.  The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids.

Authors:  Paul D W Eckford; Frances J Sharom
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

7.  PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.

Authors:  Roland B Walter; Jason L Pirga; Michelle R Cronk; Sasha Mayer; Frederick R Appelbaum; Deborah E Banker
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

Review 8.  Linker Domains: Why ABC Transporters 'Live in Fragments no Longer'.

Authors:  Robert C Ford; Dominic Marshall-Sabey; John Schuetz
Journal:  Trends Biochem Sci       Date:  2019-12-12       Impact factor: 13.807

9.  Fexofenadine hydrochloride in the treatment of allergic disease: a review.

Authors:  David Axelrod; Leonard Bielory
Journal:  J Asthma Allergy       Date:  2008-09-19

10.  Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo.

Authors:  C Zhang; S Zhai; X Li; Q Zhang; L Wu; Y Liu; C Jiang; H Zhou; F Li; S Zhang; G Su; B Zhang; B Yan
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.